Astrana Health Inc (ASTH, Financial), a notable player in the healthcare providers and services industry, has recently witnessed a significant uptick in its stock price. Over the past week, the company's shares have surged by 18.69%, and over the last three months, they have seen an overall increase of 15.89%. Currently, Astrana Health boasts a market capitalization of $2.25 billion, with a stock price standing at $49.42. This recent performance aligns with the GF Value of $51.26, suggesting that the stock is fairly valued. This is a shift from three months ago when it was considered significantly undervalued, with a GF Value of $61.
Overview of Astrana Health Inc
Astrana Health Inc is dedicated to revolutionizing patient care through its integrated population health management approach. The company primarily focuses on delivering coordinated and cost-effective medical care, especially for senior patients and those with multiple chronic conditions. Operating within the healthcare delivery segment, Astrana Health is committed to enhancing the quality of medical services through effective population health management and care coordination.
Assessing Profitability
Astrana Health's financial health is reflected in its Profitability Rank of 6/10. This rank, indicative of the company's financial stability and efficiency, is supported by several key metrics. The company's Operating Margin stands at 6.36%, which is better than 59.27% of its peers in the industry. Additionally, its Return on Equity (ROE) is 10.45%, and Return on Assets (ROA) is 5.94%, both metrics surpassing more than half of the competition. The Return on Invested Capital (ROIC) at 8.42% further underscores its ability to generate cash relative to the capital invested in the business. These figures not only highlight Astrana Health's profitability but also its capability to sustain it, having been profitable for five out of the past ten years.
Growth Trajectory
The Growth Rank of Astrana Health is 5/10, reflecting a balanced growth profile. The company has demonstrated robust growth figures, with a 3-Year Revenue Growth Rate per Share of 44.00%, ranking better than 91.05% of its industry peers. Over a 5-year period, this growth rate stands at 18.20%, again outperforming 80.82% of competitors. These metrics not only illustrate Astrana Health's growth in revenue but also its potential for future expansion within the healthcare sector.
Investor Confidence
Top investors in Astrana Health include notable figures such as Steven Cohen (Trades, Portfolio), Ray Dalio (Trades, Portfolio), and Jim Simons, holding 0.31%, 0.09%, and 0.07% of the company's shares respectively. Their investment underscores a strong confidence in the company's market strategy and future prospects.
Competitive Landscape
Astrana Health operates in a competitive environment with key players like Addus HomeCare Corp (ADUS, Financial), National Healthcare Corp (NHC, Financial), and US Physical Therapy Inc (USPH, Financial). These companies have market caps of $2.21 billion, $1.87 billion, and $1.46 billion respectively, positioning them closely with Astrana Health in terms of size and market share within the healthcare providers and services industry.
Conclusion
Astrana Health Inc's current market position is robust, characterized by a strong stock performance, solid profitability metrics, and significant growth rates. The confidence shown by top holders and the company's competitive standing within the industry further bolster its prospects. Moving forward, Astrana Health's focus on integrated population health management and care coordination is likely to continue driving its success in the healthcare market.
This article, generated by GuruFocus, is designed to provide general insights and is not tailored financial advice. Our commentary is rooted in historical data and analyst projections, utilizing an impartial methodology, and is not intended to serve as specific investment guidance. It does not formulate a recommendation to purchase or divest any stock and does not consider individual investment objectives or financial circumstances. Our objective is to deliver long-term, fundamental data-driven analysis. Be aware that our analysis might not incorporate the most recent, price-sensitive company announcements or qualitative information. GuruFocus holds no position in the stocks mentioned herein.
